BlackRock
MAZE

BlackRock’s Maze Therapeutics MAZE Stock Holding History

BlackRock’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105M Buy
3,502,841
+932,416
+36% +$24.4M ﹤0.01% 2210
2026
Q1 		$76.7M Buy
2,570,425
+283,270
+12% +$12.5M ﹤0.01% 2263
2025
Q4 		$94.8M Buy
2,287,155
+971,139
+74% +$33.4M ﹤0.01% 2134
2025
Q3 		$34.1M Buy
1,316,016
+701,312
+114% +$11.8M ﹤0.01% 2753
2025
Q2 		$7.54M Buy
614,704
+32,116
+6% +$334K ﹤0.01% 3560
2025
Q1 		$6.41M Buy
+582,588
New +$7.01M ﹤0.01% 3533

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock's MAZE Position: Q2 2026 in Review

BlackRock increased its Maze Therapeutics (MAZE) stake by 36% in Q2 2026, buying an estimated $24.4M and bringing the position to 3,502,841 shares worth $105M. The position accounts for ﹤0.01% of the portfolio, ranked #2210.

BlackRock first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • BlackRock held 3,502,841 shares of Maze Therapeutics worth $105M as of Q2 2026.
  • BlackRock bought 932,416 Maze Therapeutics shares in Q2 2026, an estimated $24.4M.
  • Maze Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2210 holding.
  • BlackRock first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.